Lexipafant ophthalmic - InSite Vision

Drug Profile

Lexipafant ophthalmic - InSite Vision

Alternative Names: ISV 611; Lexipafant - InSite Vision

Latest Information Update: 31 May 2007

Price : $50

At a glance

  • Originator British Biotech
  • Developer InSite Vision
  • Class Branched-chain amino acids; Eye disorder therapies; Imidazoles; Small molecules
  • Mechanism of Action Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Allergic conjunctivitis

Most Recent Events

  • 08 Jan 2001 No-Development-Reported for Allergic conjunctivitis in USA (Ophthalmic)
  • 30 Dec 1997 Phase-II clinical trials for Allergic conjunctivitis in USA (Ophthalmic)
  • 01 Sep 1997 Phase-I clinical trials for Allergic conjunctivitis in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top